7-19-02

Approved for use through 10/31/2002. OMP 7664,0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ollection of information unless it displays a valid OMB control number Please type a plus sign (+) inside this box Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control nuclei **Application** 10/082,521 TRANSMITTAL 02/22/02 Filing Date **FORM First Named** AGATA, et al. (to be used for all correspondence after initial for Group Art Unit JUL 1 8 2002 **Examiner Name** Total Number of Pages in This mission Attorney Docket Number 1000.06.003 **ENCLOSURES** (check all that apply) After Allowance Communication Assignment Papers Fee Transmittal Form (for an Application) Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) After Final Petition Proprietary Information Petition to Convert a Affidavits/declaration(s) Provisional Application Status Letter Power of Attorney, Revocation Other Enclosure(s) (please Change of Correspondence Extension of Time Request identify below): Copy of all references cited (not Terminal Disclaimer included in the number of pages in Express Abandonment Request submission) Request for Refund Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm STEPHEN J. MOLONEY ILEX ONCOLOGY, INC. Individual name Signature Date EL779040626US **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service w. 07/18/02 envelope addressed to: Commissioner of Patents, Washington, D.C. 20231 on this date: FRANCES WINKLER Typed or printed name Signature Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Docket No. 1000.06.003  Serial No. 10/082,521  Serial No. 10/082,521  Serial No. 10/082,521  Care Prince S  (Identify type of correspondence)  (Identify typ		OIPE	
I hereby certify that the following correspondence:  (Identify type of correspondence)  (Identify type of correspondence)  (Identify type of correspondence)  (Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on 07/18/02  (Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)		ET AL. ( JUL 1 8 2002 5)	
(Identify type of correspondence)  is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  07/18/02 (Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)	_	Filing Date PADEN Examiner 02/22/02	Group Art Unit
(Identify type of correspondence)  is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  07/18/02 (Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)	vention: TUMOR CH	EMOPOTENTIATION USING ISOCOUMARIN DERIVATIVE	S PECELVA
(Identify type of correspondence)  is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  07/18/02 (Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)		e following correspondence:	CH CENTER 1600/2900
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  07/18/02  (Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)		cierences	
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on  07/18/02  (Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)		(Identify type of correspondence)	
(Date)  FRANCES WINKLER  (Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)	is being deposited with	h the United States Postal Service "Express Mail Post Office to	Addressee" service under
(Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)	07/18	/02	Vashington, D.C. 20231 on
(Signature of Person Mailing Correspondence)  EL779040626US  ("Express Mail" Mailing Label Number)			
EL779040626US  ("Express Mail" Mailing Label Number)		(Typed or Printed Name of Person M	Tailing Correspondence)
EL779040626US  ("Express Mail" Mailing Label Number)		(Signature of Person Mailing	Correspondence)
("Express Mail" Mailing Label Number)			
Note: Each paper must have its own certificate of mailing.			
Note: Each paper must have its own certificate of mailing.			
		Note: Each paper must have its own certificate of mailing.	
			<del>-</del>

		A P P				
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))  JUL 1 8 2002  Docket No. 1000.06.003						
In Re Application Of: AGATA, ET AL.						
Serial No.	Filing Date	Examiner	Group Art Unit			
10/082,521	02/22/02		TEC			
Serial No. Filing Date Examiner Group Art Unit 10/082,521 02/22/02  Title: TUMOR CHEMOPOTENTIATION USING ISOCOUMARIN DERIVATIVES  Address to:  Assistant Commissioner for Patents						
		ddress to:				
		nmissioner for Patents gton, D.C. 20231				
		-				
	37 (	CFR 1.97(b)				
1. A The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
	37 (	CFR 1.97(c)				
2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
☐ the statement specified in 37 CFR 1.97(e);						
OR						
the fee set forth in 37 CFR 1.17(p).						
<u> </u>	7. 13. 11. 11. 11. 11. (p).					
			:			

OIPA						
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) UL 1 8 2002						
In Re Application: AGATA, ET AL.						
Serial No. 10/082,521	Filing Date 02/22/02	Examiner	Group Art Unit			
TUMOR CHEMOPOTENTIATION USING ISOCOUMARIN DERIVATIVES  TECHCENTED  Payment of Fee  (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))						
			1600			
	•	ment of Fee	000/2900			
	(Only complete if Applicant ele	ects to pay the fee set forth in 37 CFR 1.1	7(p))			
<ul> <li>□ A check in the amount of is attached.</li> <li>☑ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 501786         <ul> <li>as described below. A duplicate copy of this sheet is enclosed.</li> <li>□ Charge the amount of</li> <li>□ Credit any overpayment.</li> </ul> </li> <li>☑ Charge any additional fee required.</li> </ul>						
Certificate of 1	Fransmission by Facsimile*	Certificate of Mailing by	First Class Mail			
Certify that this document and authorization to charge deposited account is being facsimile transmitted to the United States Patent and Trademark Office (F    Certify that this document and fee is being deposited with the U.S. Postal Service as first chass mail under 37 C.F.R. 18 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231    Signature   Signature of Person Mailing Correspondence   Signature   Si						
Typed or Printed Name of Person Signing Certificate  Typed or Printed Name of Person Mailing Certificate						
*This certificate may only be used if paying by deposit account.  Dated: 17/18/02						
cc:						